Euroscreen to Present at the BIO CEO & Investor Conference

Euroscreen SA announced today that the company is scheduled to present at BIO CEO & Investor Conference on Wednesday, February 14th, 2007 at 2:15 p.m. in NYC. Jean Combalbert, Ph.D., Euroscreen's Chief Executive Officer, will provide a corporate overview of the company. This will be the company's first presentation since the €14 millions sale of its 12 year old products business to PerkinElmer, Inc. in January of this year. Following the deal, Euroscreen retained complete access and use of all of its previous reagents, procedures and patents for applications in their drug development and custom service businesses which are the focus of its future growth.

Brussels, Belgium (PRWEB) February 7, 2007 -- Euroscreen SA announced today that the company is scheduled to present at BIO CEO & Investor Conference on Wednesday, February 14th, 2007 at 2:15 p.m. in NYC. Jean Combalbert, Ph.D., Euroscreen's Chief Executive Officer, will provide a corporate overview of the company. This will be the company's first presentation since the €14 millions sale of its 12 year old products business to PerkinElmer, Inc. in January of this year. Following the deal, Euroscreen retained complete access and use of all of its previous reagents, procedures and patents for applications in their drug development and custom service businesses which are the focus of its future growth.

About Euroscreen -
Euroscreen is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for G protein-coupled receptor targets (GPCRs). Euroscreen is developing a preclinical pipeline of compounds targeting GPCRs using its extensive experience in research with this critical class of drug targets. Its internal programs are focused upon unmet medical needs, with a particular interest in inflammation diseases.

The Company owns a broad GPCR patent portfolio for out-licensing to biotech and pharmaceutical companies. Such patents address targets such as CCR5, Chemerin receptor, GPR43, GPR7/8, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

Euroscreen's strategy is focused on its own internal drug discovery and partnered research collaborations. Euroscreen also serves biotech and pharmaceutical companies around the world, with its high performance, custom screening platform - Euroscreen FAST.

Euroscreen has research collaborations with Cephalon, ChemDiv, Alchemia as well as additional partnerships with GNF, ICOS, HGS, Medarex, Novartis and Pfizer. Euroscreen is a privately held company based in Brussels, Belgium. (www.euroscreen.com)

Contacts:
Jean Combalbert, Ph.D.
Chief Executive Officer
                   
Alfred Gray, Ph.D.
Vice President Business Dev.
+32 71 34 85 00
http://www.euroscreen.com/

###